PAS
SRPT icon

Point72 Asia (Singapore)’s Sarepta Therapeutics SRPT Stock Holding History

Point72 Asia (Singapore)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,611
Closed -$338K – 1466
2024
Q1 		$338K Buy
+2,611
New +$320K 0.09% 254

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asia (Singapore)'s SRPT Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 2,611 shares — an estimated $338K sold.

Point72 Asia (Singapore) first reported a position in SRPT in Q1 2024 and held it in 1 quarter. The position peaked at $338K in Q1 2024. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 2,611 Sarepta Therapeutics shares in Q2 2024, an estimated $338K.
  • Point72 Asia (Singapore) first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Sarepta Therapeutics position peaked at $338K in Q1 2024.
  • 483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.